Quoin in line for second priority review voucher if rare paediatric drug approved - Pharmaceutical Technology

Quoin has now received two rare paediatric disease designations for its lead asset QRX003. Quoin has now received two rare paediatric disease designations for its lead asset QRX003. Vouchers can be sold, with current prices between $150m and $200m apiece. Credit: Tada Images/Shutterstock.com. The US Food and Drug Administration (FDA) has granted rare paediatric disease designation to Quoin Pharmaceuticals’ candidate in development for the treatment of Peeling Skin Syndrome (PSS), marking the second tag of this nature for the biotech’s lead asset. As per the designation, Quoin will be eligible to receive a priority review voucher if the candidate –…

Source: Pharmaceutical Technology